Visceral Fat and Heart Disease in Men: The Fat That Counts

A man can be normal weight by BMI and still carry enough visceral fat to significantly elevate his cardiovascular risk. Visceral adipose tissue, the fat that accumulates inside the abdominal cavity surrounding the liver, intestines, and kidneys, is metabolically active in ways that subcutaneous fat is not. It secretes inflammatory cytokines, drives insulin resistance, suppresses adiponectin, and generates free fatty acids that overwhelm hepatic lipid clearance. Understanding why this matters, why BMI misses it, and what actually reduces it is foundational to men’s cardiovascular risk management.

The phenomenon has a name in the clinical literature: metabolically obese normal weight, or MONW. A man in this category registers a BMI under 25, falls outside the traditional obesity risk categories, and is often assessed as low metabolic risk based on the absence of obesity. But his actual cardiovascular risk profile, driven by visceral fat that does not register in the BMI calculation, may be comparable to or worse than that of a man who is visibly overweight but distributes his excess fat subcutaneously rather than viscerally. BMI was designed as a population-level screening tool and was never validated as an individual-level metabolic risk measure. The gap between what BMI measures and what drives cardiovascular disease in men is clinically consequential and increasingly well documented.

BMI’s Fundamental Limitation

BMI divides weight in kilograms by height in meters squared and produces a single number that captures neither body composition nor fat distribution. Two men with identical BMI of 26 can have fundamentally different cardiovascular risk profiles: one with 18 percent body fat concentrated subcutaneously, one with 30 percent body fat concentrated viscerally. The man with normal BMI and high visceral fat may have elevated triglycerides, low HDL, elevated fasting glucose, and early insulin resistance, while the man with higher total fat but subcutaneous distribution may have metabolically normal lipids, glucose, and blood pressure.

Normal-weight obesity, the clinical pattern of normal BMI with excess body fat, is estimated to affect 15 to 25 percent of middle-aged men in developed countries. These men are systematically missed by BMI-based screening because their weight is within the reference range. Their cardiovascular risk is not. In cohort studies, normal-weight men with high visceral fat have higher rates of coronary artery disease, diabetes progression, and cardiovascular mortality than men with higher BMI but lower visceral fat, which inverts the standard BMI-based risk prediction completely.

The MESA (Multi-Ethnic Study of Atherosclerosis) study demonstrated that CT-measured visceral adipose tissue was a stronger predictor of coronary artery calcium score progression than BMI or waist circumference alone. Since coronary artery calcium represents actual atherosclerotic plaque burden, this finding establishes a direct mechanistic link between visceral fat and the structural vascular disease that eventually causes myocardial infarction.

Waist circumference is the most practical clinical proxy for visceral fat available in a standard clinical encounter. A waist circumference above 40 inches (102 cm) in men is associated with elevated metabolic risk. The threshold for women is 35 inches (88 cm), reflecting the fact that men preferentially deposit visceral fat relative to subcutaneous fat at lower total fat percentages. A man with a 44-inch waist and a normal BMI has a visceral fat signal that his BMI completely obscures; a standard clinical assessment that reads only his BMI and finds it normal will miss this signal entirely.

Why Men Store Fat Viscerally

Sex hormones direct fat distribution in ways that are well established. Testosterone promotes visceral fat deposition and inhibits subcutaneous fat expansion; estrogen promotes subcutaneous fat deposition in gluteal and femoral regions. This hormonal programming means that at any given level of total fat, men carry more of it viscerally than women. The sex difference in fat distribution is not simply about total adiposity; it is about where that adiposity goes.

As testosterone declines with age in men, at approximately 1 to 2 percent per year after age 30 and accelerating after 50, the testosterone-estrogen balance shifts. Testosterone’s inhibitory effect on subcutaneous fat expansion and its promotion of visceral deposition produce a pattern where, with declining testosterone, men do not simply develop more fat overall; they accumulate it preferentially in the visceral compartment. Men who are hypogonadal accumulate visceral fat faster than eugonadal men at equivalent ages, which creates a cycle where visceral fat drives aromatase activity (visceral adipocytes contain high levels of aromatase, the enzyme that converts testosterone to estrogen), further reducing testosterone and accelerating the shift.

After age 50, most men’s waist circumference increases even without significant weight gain. This is not simply a matter of caloric excess; it reflects redistribution from subcutaneous to visceral compartments as the hormonal balance shifts with age. A man who is not gaining weight on the scale but whose belt is progressively tighter is experiencing the visceral redistribution that is characteristic of male aging, and his cardiovascular risk is increasing even as his scale weight remains stable.

Stress-related cortisol elevation is another major driver of visceral fat deposition in men. The hypothalamic-pituitary-adrenal axis activation from chronic work stress, sleep deprivation, social isolation, or financial stress preferentially drives central fat accumulation. Visceral adipocytes have higher glucocorticoid receptor density than subcutaneous adipocytes, which makes them particularly responsive to cortisol-driven lipid uptake. The middle-aged man under chronic occupational stress with a growing waist circumference and stable weight is demonstrating the cortisol-visceral fat axis operating in a way that BMI will never detect.

What Visceral Fat Does Biologically

Visceral adipocytes are more metabolically active than subcutaneous adipocytes. They have a higher lipolytic rate, greater sensitivity to catecholamines, and are positioned anatomically to drain their metabolic products directly into the portal circulation, which flows to the liver before entering the systemic circulation. This portal drainage is the key to understanding why visceral fat has disproportionate metabolic consequences.

The free fatty acid (FFA) flux from visceral fat through the portal circulation to the liver produces hepatic insulin resistance through a direct lipid-loading mechanism. When the liver is chronically exposed to high FFA flux, it develops reduced insulin sensitivity, which drives compensatory hyperinsulinemia. Hyperinsulinemia signals the liver to increase very low-density lipoprotein (VLDL) secretion. Elevated VLDL drives hypertriglyceridemia and, through cholesterol ester transfer protein activity, simultaneously reduces HDL levels. The VLDL particles also produce small, dense LDL particles through hepatic lipase activity; small dense LDL is more atherogenic than large buoyant LDL because it penetrates the arterial wall more readily, has longer half-life in circulation, and is more susceptible to oxidative modification.

This sequence, visceral fat to portal FFA flux to hepatic insulin resistance to elevated VLDL to hypertriglyceridemia, low HDL, and small dense LDL, is the mechanism behind the atherogenic dyslipidemia pattern that characterizes metabolic syndrome in men. It explains why a man with visceral obesity can have LDL-C that appears acceptable while carrying substantially elevated cardiovascular risk through the small dense LDL and ApoB elevation that standard LDL-C measurement misses.

IL-6 secretion from visceral adipocytes drives hepatic C-reactive protein production, producing the elevated hs-CRP that represents the inflammatory arm of visceral fat’s cardiovascular effects. TNF-alpha secretion from visceral fat drives further insulin resistance in peripheral tissues and promotes endothelial adhesion molecule expression, facilitating monocyte entry into the arterial wall and accelerating atherosclerosis. Adiponectin, a protein secreted by adipocytes with anti-inflammatory, insulin-sensitizing, and endothelial-protective properties, is suppressed in visceral obesity; its loss removes protections that normally operate continuously in men with healthier fat distribution.

Non-alcoholic fatty liver disease (NAFLD) is largely a consequence of visceral fat-driven FFA overload of the liver. NAFLD itself is an independent cardiovascular risk factor, not simply a metabolic curiosity; men with NAFLD have higher rates of coronary artery disease, left ventricular dysfunction, and cardiovascular mortality independent of the traditional risk factors that commonly co-occur with it. The visceral fat to NAFLD to cardiovascular risk pathway represents a convergence point where the multiple mechanisms of visceral fat damage produce measurable hepatic and cardiac structural consequences.

The Metabolic Syndrome Pattern in Men

Metabolic syndrome in men typically presents as central obesity combined with hypertriglyceridemia, low HDL, elevated fasting glucose, and elevated blood pressure. The ATP III definition requires three of five criteria, with abdominal obesity the most common entry criterion in men. The Framingham Heart Study and subsequent cohorts consistently demonstrate that men with metabolic syndrome have approximately three times the cardiovascular disease risk of metabolically healthy weight-matched controls.

The triglyceride-to-HDL ratio is a useful clinical marker of insulin resistance and visceral fat-driven atherogenic dyslipidemia. A ratio above 3.5 in men (triglycerides in mg/dL divided by HDL in mg/dL) is associated with high prevalence of insulin resistance and small dense LDL. This calculation requires only a fasting lipid panel and takes seconds to perform; it provides a window into the atherogenic dyslipidemia pattern that LDL-C alone will miss.

In men with metabolic syndrome, ApoB is frequently elevated even when LDL-C appears acceptable. This is the cardiovascular risk translation of the small dense LDL pattern: more LDL particles at lower cholesterol content per particle, producing normal LDL-C but elevated particle count (ApoB). Since it is the number of LDL particles rather than their cholesterol content that drives endothelial penetration and plaque formation, ApoB is a more accurate cardiovascular risk marker than LDL-C in men with metabolic syndrome and visceral obesity. Some cardiologists now routinely order ApoB in men with metabolic syndrome regardless of LDL-C, specifically because this pattern is so prevalent and so commonly missed.

The INTERHEART study, which enrolled patients across 52 countries to characterize modifiable risk factors for MI, found that waist-to-hip ratio was a more powerful predictor of myocardial infarction than BMI across all ethnic groups and geographic regions studied. 5 / Solid This finding, from one of the largest epidemiological studies of MI risk ever conducted, directly establishes fat distribution rather than total body weight as the critical cardiovascular variable. The man with a high waist-to-hip ratio in Lagos faces the same MI risk elevation as the man with a high waist-to-hip ratio in Toronto; the relationship is not specific to any dietary pattern, ethnic background, or healthcare system.

Measuring Visceral Fat Clinically

The gold standard for visceral fat measurement is CT or MRI measurement of visceral adipose tissue area at the L4-L5 vertebral level. This approach is accurate, reproducible, and used extensively in research. It is not practically available as a screening tool in routine clinical practice.

Waist circumference, measured at the umbilicus with the patient standing and exhaling normally, is practical, reproducible, and clinically meaningful. It should be measured in every cardiovascular assessment of men over 40. A baseline measurement allows tracking over time; a man whose waist circumference is increasing by 1 to 2 inches per year over a decade is experiencing the kind of visceral fat accumulation that corresponds to measurable metabolic and cardiovascular risk deterioration, even if his scale weight barely changes.

The waist-to-height ratio (WHtR) provides an adjustment for body scale. A ratio above 0.5, meaning the waist circumference is more than half the standing height, is a reasonable threshold for elevated visceral fat risk in men. Some of the evidence shows the WHtR outperforms both BMI and waist circumference alone for cardiovascular risk prediction, particularly in shorter men for whom the absolute 40-inch waist threshold is less appropriate.

DEXA scan, available in many clinical settings for bone density assessment, can estimate visceral versus subcutaneous fat in an android distribution measurement that is obtained during the same scan used for osteoporosis screening. This is not routine practice but represents an option for men who are already receiving DEXA for other reasons and where precise body composition information would change management. Bioelectrical impedance is widely available in clinical practice and is useful for trending total body fat over time, though it is less accurate for distinguishing visceral from subcutaneous fat compartments specifically.

For men who ask which number matters most, the practical answer is waist circumference measured consistently over time, combined with fasting triglycerides, HDL, fasting glucose, and blood pressure. These five values capture the metabolic syndrome profile that visceral fat drives, in a panel that is available at any clinical laboratory and interpretable immediately. ApoB adds resolution in men where LDL-C appears acceptable but the clinical picture suggests metabolic syndrome.

What Actually Reduces Visceral Fat

Aerobic exercise is the most reliably visceral-fat-specific intervention across the literature. Consistent evidence from randomized trials and large cohort studies shows that aerobic activity reduces visceral adipose tissue even without significant weight loss, through mechanisms that include improved insulin sensitivity, reduced cortisol through stress-pathway normalization, and catecholamine-mediated lipolysis that preferentially mobilizes visceral fat relative to subcutaneous fat. Men who maintain 150 to 200 minutes per week of moderate-intensity aerobic exercise have substantially lower visceral fat than sedentary men matched for total body weight.

Resistance training reduces visceral fat to a lesser degree than aerobic exercise in head-to-head comparisons, but combinations of aerobic and resistance training show additive visceral fat reduction. For men who are primarily engaged in resistance training without aerobic exercise, adding even 30 minutes of moderate aerobic activity three to four days per week produces measurable visceral fat reduction. The two modalities appear to address different mechanisms: aerobic exercise primarily through enhanced insulin sensitivity and lipolysis, resistance training through increases in metabolically active lean mass that raise resting energy expenditure.

Caloric restriction is necessary for significant and sustained visceral fat reduction in men with established visceral obesity. The composition of the caloric deficit matters less than the deficit itself for total fat loss, though low-carbohydrate diets show faster visceral fat reduction in short-term trials of 6 to 12 weeks, possibly because carbohydrate restriction lowers insulin levels, which reduces lipid uptake into adipocytes and mobilizes stored fat more readily. Mediterranean dietary pattern, which is not a strict low-carbohydrate approach, consistently reduces visceral fat and cardiovascular risk markers in randomized trials, likely through the combination of moderate carbohydrate quality, polyphenol content, and anti-inflammatory fatty acid profile.

Alcohol reduction is a visceral-fat intervention that is frequently underemphasized. Alcohol is preferentially converted to acetate in the liver, which inhibits fat oxidation, and alcohol consumption drives visceral fat deposition more than subcutaneous fat deposition. Men who reduce heavy alcohol use consistently show reductions in waist circumference and visceral fat independent of other dietary changes. A man consuming more than 14 standard drinks per week and complaining of growing waist circumference will not achieve sustainable visceral fat reduction without addressing his alcohol intake, regardless of other dietary or exercise interventions.

Sleep quantity and quality are visceral fat determinants. Chronic sleep restriction below 6 hours per night increases visceral fat accumulation independently of diet and exercise through multiple mechanisms, including elevated cortisol from sleep deprivation, increased ghrelin (appetite-stimulating hormone), decreased leptin (satiety hormone), and impaired glucose metabolism. For a man working night shifts, regularly sleeping 5 hours, or experiencing sleep-disordered breathing (obstructive sleep apnea is itself a source of visceral fat accumulation through cortisol and hypoxia-related pathways), improving sleep is a visceral fat intervention with independent cardiovascular benefit.

GLP-1 receptor agonists, including semaglutide and tirzepatide, produce substantial visceral fat reduction as part of their mechanism of action. Body composition studies during semaglutide and tirzepatide trials have shown 5 to 15 percent reduction in visceral adipose tissue at standard doses, with proportionally greater visceral fat loss than subcutaneous fat loss. 4 / Promising The cardiovascular benefit observed in the SELECT trial (semaglutide in men and women with obesity and established CVD, without diabetes) is partly attributed to visceral fat reduction, though the precise mechanistic contribution of visceral fat versus other effects of GLP-1 agonism remains under investigation. SGLT2 inhibitors also produce modest but consistent visceral fat reduction as part of their cardiometabolic mechanism, contributing to the cardiorenal benefits observed in those trials.

The Testosterone Interaction

Testosterone replacement in clearly hypogonadal men, defined as biochemically confirmed low testosterone with symptoms, reliably reduces visceral fat and improves insulin sensitivity in randomized clinical trials. The mechanism operates through testosterone’s direct effects on adipocyte metabolism and the reversal of the visceral fat accumulation that hypogonadism drives. This is not a trivial effect; some trials have shown visceral fat reductions of 10 to 15 percent with testosterone normalization in genuinely hypogonadal men.

The TRAVERSE trial, which enrolled 5,246 men with hypogonadism and established cardiovascular disease or high cardiovascular risk, assessed the cardiovascular safety of testosterone replacement over a median follow-up of approximately 33 months. Testosterone was non-inferior to placebo for major adverse cardiovascular events. However, the trial identified a signal for increased atrial fibrillation (3.5 percent vs 2.4 percent) and pulmonary embolism (0.9 percent vs 0.5 percent) in the testosterone group, which warrants monitoring in clinical practice. 5 / Solid

The metabolic benefit of restoring testosterone in hypogonadal men, including visceral fat reduction and insulin sensitivity improvement, is real and biologically meaningful. The TRAVERSE cardiovascular safety evidence is now more complete than before the trial, but the AF and PE signals require consideration when deciding whether to initiate testosterone in men with pre-existing cardiovascular disease. In eugonadal men with visceral obesity, testosterone is not indicated for fat reduction; lifestyle intervention, not androgen supplementation, is the primary approach in men with normal testosterone and high visceral fat.

Synthesis: Why Measuring the Right Thing Matters

The gap between BMI-based cardiovascular risk assessment and visceral-fat-centered assessment is not a minor academic distinction. It is the difference between correctly identifying men whose cardiovascular risk profile is driven by a physiologically active fat depot and incorrectly categorizing them as low risk because their scale weight falls within a reference range.

Some cardiologists now treat waist circumference as a mandatory measurement in men over 40, with ApoB as the lipid marker that captures the atherogenic dyslipidemia pattern that visceral fat drives more accurately than LDL-C alone. That approach is more consistent with the evidence on cardiovascular risk in men than the standard BMI plus standard lipid panel combination that dominates routine practice.

The interventions with the strongest evidence for visceral fat reduction, aerobic exercise, dietary modification with caloric deficit, alcohol reduction, sleep improvement, and in appropriate patients GLP-1 receptor agonists, are available, effective, and align with cardiovascular risk reduction through multiple overlapping mechanisms. They work not just through visceral fat but through the downstream effects of visceral fat on insulin resistance, atherogenic dyslipidemia, systemic inflammation, and endothelial function. Reducing visceral fat in a man with central obesity is not simply a cosmetic or weight management goal; it is a primary cardiovascular intervention operating upstream of the lipid and inflammatory markers that eventually drive the events that cardiology is trying to prevent.

The evidence framework for visceral fat as a male cardiovascular risk driver is not theoretical. It is established across large cohort studies, mechanistic research, and trials of interventions that modify visceral fat and produce corresponding cardiovascular benefit. What remains is more consistent application of that framework in clinical practice, starting with measuring waist circumference in every man who walks through a cardiology clinic door and asking what it means rather than defaulting to BMI as the opening question about adipose-related cardiovascular risk.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.